Dawn I Velligan1, Megan Fredrick2, Jim Mintz2, Xueying Li2, Maureen Rubin3, Sanjay Dube4, Smita N Deshpande5, Jitendra K Trivedi6, Shiv Gautam7, Ajit Avasthi8, Robert S Kern9, Stephen R Marder10. 1. Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX; velligand@uthscsa.edu. 2. Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX; 3. Department of Social Work, University of Texas at San Antonio, San Antonio, TX; 4. Eli Lilly and Company, Indianapolis, IN; 5. Postgraduate Institute of Medical Education & Research, Dr. Ram Manohar Lohia Hospital, New Delhi, India; 6. CSM Medical University, Lucknow, India; 7. Gautam Institute of Behavioral Sciences and Alternative Medicine, NIMS Medical College and University, Jaipur, India; 8. Postgraduate Institute of Medical Education & Research, Chandigarh, India; 9. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA; 10. Semel Institute for Neuroscience, University of California, Los Angeles and VA Desert Pacific Mental Illness Research, Education and Clinical Center, Los Angeles, CA.
Abstract
OBJECTIVES: The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was designed to encourage the development of cognitive enhancing agents for schizophrenia. For a medication to receive this indication, regulatory agencies require evidence of improvement in both cognition and functional outcome. Functional capacity measures typically used in clinical trials as intermediate measures of functional outcome must be adapted to fit different cultural contexts for use internationally. We examined the psychometric properties of the MATRICS Functional Assessment Battery (MFAB), comprised of 2 subtests from the UCSD Performance-based Skills Assessment (UPSA) and one from the Test of Adaptive Behavior in Schizophrenia (TABS) that were rated by experts in a previous study to be the most appropriate functional capacity assessments across different cultural contexts. METHOD: Four sites in India administered the MFAB, a brief version of the UPSA, the MATRICS Cognitive Consensus Battery, measures of symptomatology, and a measure of global functional outcome to 141 individuals with schizophrenia at a baseline assessment and at 4 weeks later. RESULTS: Test-retest reliability based on the intraclass correlation coefficient was significantly better for the UCSD Performance-Based Skills Assessment-Brief (UPSA-B). Pearson correlation coefficients over time were not significantly different for the 2 measures. Only the MFAB was significantly correlated with functional outcome as measured by the Specific Levels of Functioning Scale. CONCLUSIONS: The psychometric properties of the MFAB and UPSA-B were similar. The MATRICS scientific board chose to translate the MFAB into multiple languages for potential use in studies of novel medications seeking an indication for improving cognition in schizophrenia.
OBJECTIVES: The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was designed to encourage the development of cognitive enhancing agents for schizophrenia. For a medication to receive this indication, regulatory agencies require evidence of improvement in both cognition and functional outcome. Functional capacity measures typically used in clinical trials as intermediate measures of functional outcome must be adapted to fit different cultural contexts for use internationally. We examined the psychometric properties of the MATRICS Functional Assessment Battery (MFAB), comprised of 2 subtests from the UCSD Performance-based Skills Assessment (UPSA) and one from the Test of Adaptive Behavior in Schizophrenia (TABS) that were rated by experts in a previous study to be the most appropriate functional capacity assessments across different cultural contexts. METHOD: Four sites in India administered the MFAB, a brief version of the UPSA, the MATRICS Cognitive Consensus Battery, measures of symptomatology, and a measure of global functional outcome to 141 individuals with schizophrenia at a baseline assessment and at 4 weeks later. RESULTS: Test-retest reliability based on the intraclass correlation coefficient was significantly better for the UCSD Performance-Based Skills Assessment-Brief (UPSA-B). Pearson correlation coefficients over time were not significantly different for the 2 measures. Only the MFAB was significantly correlated with functional outcome as measured by the Specific Levels of Functioning Scale. CONCLUSIONS: The psychometric properties of the MFAB and UPSA-B were similar. The MATRICS scientific board chose to translate the MFAB into multiple languages for potential use in studies of novel medications seeking an indication for improving cognition in schizophrenia.
Authors: Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Dawn I Velligan; Pamela Diamond; David C Glahn; Janice Ritch; Natalie Maples; Desiree Castillo; Alexander L Miller Journal: Psychiatry Res Date: 2007-03-26 Impact factor: 3.222
Authors: Christopher M Wilk; James M Gold; John J Bartko; Faith Dickerson; Wayne S Fenton; Michael Knable; Christopher Randolph; Robert W Buchanan Journal: Am J Psychiatry Date: 2002-05 Impact factor: 18.112
Authors: Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Robin Michael Van Eck; Thijs Jan Burger; Astrid Vellinga; Frederike Schirmbeck; Lieuwe de Haan Journal: Schizophr Bull Date: 2018-04-06 Impact factor: 9.306
Authors: Raeanne C Moore; Alexandrea L Harmell; Philip D Harvey; Christopher R Bowie; Colin A Depp; Ann E Pulver; John A McGrath; Thomas L Patterson; Veronica Cardenas; Paula Wolyniec; Mary H Thornquist; James R Luke; Barton W Palmer; Dilip V Jeste; Brent T Mausbach Journal: Schizophr Res Date: 2015-10-01 Impact factor: 4.939
Authors: Raeanne C Moore; Pariya L Fazeli; Thomas L Patterson; Colin A Depp; David J Moore; Eric Granholm; Dilip V Jeste; Brent T Mausbach Journal: Schizophr Res Date: 2015-03-16 Impact factor: 4.939
Authors: Sreelatha S Narayanan; Triptish Bhatia; Dawn I Velligan; Vishwajit L Nimgaonkar; Smita N Deshpande Journal: Schizophr Res Date: 2015-10-31 Impact factor: 4.939
Authors: Anthony J Rissling; Makoto Miyakoshi; Catherine A Sugar; David L Braff; Scott Makeig; Gregory A Light Journal: Neuroimage Clin Date: 2014-10-01 Impact factor: 4.881
Authors: Richard S E Keefe; George M Haig; Stephen R Marder; Philip D Harvey; Eduardo Dunayevich; Alice Medalia; Michael Davidson; Ilise Lombardo; Christopher R Bowie; Robert W Buchanan; Dragana Bugarski-Kirola; William T Carpenter; John T Csernansky; Pedro L Dago; Dante M Durand; Frederick J Frese; Donald C Goff; James M Gold; Christine I Hooker; Alex Kopelowicz; Antony Loebel; Susan R McGurk; Lewis A Opler; Amy E Pinkham; Robert G Stern Journal: Schizophr Bull Date: 2015-09-11 Impact factor: 9.306
Authors: Chika Sumiyoshi; Manbu Takaki; Yuko Okahisa; Thomas L Patterson; Philip D Harvey; Tomiki Sumiyoshi Journal: Schizophr Res Cogn Date: 2014-10-12